GH Research PLC (GHRS)
NASDAQ: GHRS · Real-Time Price · USD
10.13
-0.83 (-7.55%)
Nov 21, 2024, 1:18 PM EST - Market open
GH Research Employees
GH Research had 49 employees as of December 31, 2023. The number of employees increased by 17 or 53.13% compared to the previous year.
Employees
49
Change (1Y)
17
Growth (1Y)
53.13%
Revenue / Employee
n/a
Profits / Employee
-$845,531
Market Cap
526.78M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 49 | 17 | 53.13% |
| Dec 31, 2022 | 32 | 18 | 128.57% |
| Dec 31, 2021 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Community Health Systems | 61,000 |
| Theravance Biopharma | 99 |
| PureTech Health | 90 |
| Olema Pharmaceuticals | 74 |
| Terns Pharmaceuticals | 66 |
| Altimmune | 59 |
| Astria Therapeutics | 59 |
| Cartesian Therapeutics | 38 |
GHRS News
- 7 days ago - GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 2 months ago - GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 2 months ago - GH Research Announces Appointment of Dr. Velichka “Villy” Valcheva to Chief Executive Officer - GlobeNewsWire
- 7 months ago - GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 9 months ago - GH Research Reports Full Year 2023 Financial Results and Provides Business Updates - GlobeNewsWire
- 10 months ago - GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression - GlobeNewsWire
- 1 year ago - GH Research Reports Third Quarter Financial Results and Provides Business Updates - GlobeNewsWire
- 1 year ago - GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression - GlobeNewsWire